Novartis: makes offer to buy French gene therapy firm
(CercleFinance.com) - Swiss drugmaker Novartis has made an offer to buy gene therapy company CellforCure from French pharmaceutical group LFB for an undisclosed sum.
Under the terms of the deal, Novartis will acquire CellforCure's manufacturing facility located in Les Ulis, a suburb to the south west of Paris, and the related adjacent land, the company said.
If the offer is accepted, CellforCure would become a wholly-owned Novartis manufacturing site, joining a network of cell and gene therapy sites that already includes Morris Plains, New Jersey, and Stein, Switzerland.
Earlier this year, Novartis signed an agreement with CellforCure to produce CAR-T cell therapies, including cancer drug Kymriah.
Novartis also said today that the European Commission has given its go-ahead for an expanded indication of Kisqali, now approved for pre- and peri-menopausal women with HR+/HER2- locally advanced or metastatic breast cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the deal, Novartis will acquire CellforCure's manufacturing facility located in Les Ulis, a suburb to the south west of Paris, and the related adjacent land, the company said.
If the offer is accepted, CellforCure would become a wholly-owned Novartis manufacturing site, joining a network of cell and gene therapy sites that already includes Morris Plains, New Jersey, and Stein, Switzerland.
Earlier this year, Novartis signed an agreement with CellforCure to produce CAR-T cell therapies, including cancer drug Kymriah.
Novartis also said today that the European Commission has given its go-ahead for an expanded indication of Kisqali, now approved for pre- and peri-menopausal women with HR+/HER2- locally advanced or metastatic breast cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.